A cohort study of COVID-19 infection in pediatric oncology patients plus the utility and safety of remdesivir treatment
Retrospective 18 immunocompromised pediatric COVID-19 patients in Singapore, showing slower viral clearance with remdesivir, without statistical significance.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
|
recovery time, 75.0% higher, relative time 1.75, p = 0.60, treatment 4, control 14, defervescence.
|
|
hospitalization time, 55.6% higher, relative time 1.56, p = 0.31, treatment 4, control 14.
|
|
time to viral-, 60.7% higher, relative time 1.61, p = 0.14, treatment 4, control 14.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Ong et al., 20 Jan 2023, retrospective, Singapore, peer-reviewed, 12 authors.
Contact:
rina.ong.yl@kkh.com.sg, yung.chee.fu@singhealth.com.sg.
Abstract: Acta Oncologica
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ionc20
A cohort study of COVID-19 infection in pediatric
oncology patients plus the utility and safety of
remdesivir treatment
Rina Yue Ling Ong, Valerie Xue Fen Seah, Chia Yin Chong, Koh Cheng Thoon,
Natalie Woon Hui Tan, Jiahui Li, Karen Donceras Nadua, Shui Yen Soh,
Michaela Su-Fern Seng, Thi Ngoc Anh Pham, Chee Fu Yung & Kai-Qian Kam
To cite this article: Rina Yue Ling Ong, Valerie Xue Fen Seah, Chia Yin Chong, Koh Cheng
Thoon, Natalie Woon Hui Tan, Jiahui Li, Karen Donceras Nadua, Shui Yen Soh, Michaela Su-Fern
Seng, Thi Ngoc Anh Pham, Chee Fu Yung & Kai-Qian Kam (2023) A cohort study of COVID-19
infection in pediatric oncology patients plus the utility and safety of remdesivir treatment, Acta
Oncologica, 62:1, 53-57, DOI: 10.1080/0284186X.2023.2169079
To link to this article: https://doi.org/10.1080/0284186X.2023.2169079
Published online: 20 Jan 2023.
Submit your article to this journal
Article views: 470
View related articles
View Crossmark data
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ionc20
ACTA ONCOLOGICA
2023, VOL. 62, NO. 1, 53–57
https://doi.org/10.1080/0284186X.2023.2169079
LETTER TO THE EDITOR
A cohort study of COVID-19 infection in pediatric oncology patients plus the
utility and safety of remdesivir treatment
Rina Yue Ling Onga , Valerie Xue Fen Seaha , Chia Yin Chongb,c,d,e , Koh Cheng Thoonb,c,d,e ,
Natalie Woon Hui Tanb,c,d,e , Jiahui Lib,c,d,e, Karen Donceras Naduab,c,d,e , Shui Yen Sohc,d,e,f ,
Michaela Su-Fern Sengc,d,e,f , Thi Ngoc Anh Phamg, Chee Fu Yungb,d,e
and Kai-Qian Kamb,c,d,e
a
Department of Pharmacy, KK Women’s and Children’s Hospital, Singapore, Singapore; bInfectious Disease Service, Department of Pediatrics,
KK Women’s and Children’s Hospital, Singapore, Singapore; cYong Loo Lin School of Medicine, National University of Singapore, Singapore,
Singapore; dDuke-National University of Singapore Medical School, Singapore, Singapore; eLee Kong Chian School of Medicine, Nanyang
Technological University, Singapore, Singapore; fHaematology/Oncology Service, Department of Pediatrics, KK Women’s and Children’s
Hospital, Singapore, Singapore; gNursing Clinical Services, Division of Nursing, KK Women’s and Children’s Hospital, Singapore, Singapore
ARTICLE HISTORY Received 22 November 2022; Accepted 11 January 2023
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
